Royalty Pharma plc (NASDAQ: RPRX) Stock Competitors & Peer Comparison

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CORT trades at $114.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CORT's P/E ratio is 326.37. In terms of profitability, RPRX's ROE is +0.12%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas WBA's P/E ratio is -1.64. In terms of profitability, RPRX's ROE is +0.12%, compared to WBA's ROE of -0.42%. Regarding short-term risk, RPRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check WBA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, LQDA has a market cap of 8.1B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while LQDA trades at $91.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas LQDA's P/E ratio is 650.21. In terms of profitability, RPRX's ROE is +0.12%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RPRX is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LQDA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while KNSA trades at $76.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas KNSA's P/E ratio is 85.03. In terms of profitability, RPRX's ROE is +0.12%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check KNSA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while TRLV trades at $9.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas TRLV's P/E ratio is -21.50. In terms of profitability, RPRX's ROE is +0.12%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, RPRX is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check TRLV's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas HROWL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, RPRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas HROWM's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, RPRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWM's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, LTGO has a market cap of 1.1B. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while LTGO trades at $18.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas LTGO's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to LTGO's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LTGO's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CUVL has a market cap of 339.9M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CUVL trades at $6.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CUVL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CUVL's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CUVL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, LFMD has a market cap of 175.1M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while LFMD trades at $3.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas LFMD's P/E ratio is -7.24. In terms of profitability, RPRX's ROE is +0.12%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, RPRX is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LFMD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, LFMDP has a market cap of 160.2M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while LFMDP trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas LFMDP's P/E ratio is -724.19. In terms of profitability, RPRX's ROE is +0.12%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, RPRX is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check LFMDP's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CIRC has a market cap of 63M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CIRC trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CIRC's P/E ratio is -1.59. In terms of profitability, RPRX's ROE is +0.12%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, RPRX is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CIRC's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas RAD's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to RAD's ROE of +2.76%. Regarding short-term risk, RPRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check RAD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas GLTO's P/E ratio is -1.78. In terms of profitability, RPRX's ROE is +0.12%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, RPRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check GLTO's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, SCYX has a market cap of 32.4M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while SCYX trades at $5.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas SCYX's P/E ratio is -1.51. In terms of profitability, RPRX's ROE is +0.12%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, RPRX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCYX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, NSRX has a market cap of 29.4M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while NSRX trades at $3.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas NSRX's P/E ratio is -4.74. In terms of profitability, RPRX's ROE is +0.12%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, RPRX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check NSRX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, SDEV has a market cap of 27.6M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while SDEV trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas SDEV's P/E ratio is -0.18. In terms of profitability, RPRX's ROE is +0.12%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, RPRX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SDEV's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CNSY has a market cap of 26.4M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CNSY trades at $3.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CNSY's P/E ratio is -0.53. In terms of profitability, RPRX's ROE is +0.12%, compared to CNSY's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CNSY's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, BFRI has a market cap of 15.5M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while BFRI trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas BFRI's P/E ratio is -1.13. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, RPRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRI's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CJJD's P/E ratio is -0.46. In terms of profitability, RPRX's ROE is +0.12%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, RPRX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CJJD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas SSY's P/E ratio is -2.86. In terms of profitability, RPRX's ROE is +0.12%, compared to SSY's ROE of -0.09%. Regarding short-term risk, RPRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SSY's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, POM has a market cap of 7.3M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while POM trades at $1.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas POM's P/E ratio is -0.21. In terms of profitability, RPRX's ROE is +0.12%, compared to POM's ROE of +0.16%. Regarding short-term risk, RPRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POM's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, PAVS has a market cap of 6.4M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while PAVS trades at $7.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas PAVS's P/E ratio is -0.08. In terms of profitability, RPRX's ROE is +0.12%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, RPRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PAVS's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while HKPD trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas HKPD's P/E ratio is -6.99. In terms of profitability, RPRX's ROE is +0.12%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, RPRX is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HKPD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, AIXC has a market cap of 4.1M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while AIXC trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas AIXC's P/E ratio is -0.09. In terms of profitability, RPRX's ROE is +0.12%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, RPRX is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check AIXC's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas MDVL's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, RPRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check MDVL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas ATNFW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, RPRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATNFW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, RPRX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMSP's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while BGMS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas BGMS's P/E ratio is -0.25. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, RPRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMS's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas AZNH's P/E ratio is 38.35. In terms of profitability, RPRX's ROE is +0.12%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, RPRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check AZNH's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, RPRX's ROE is +0.12%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, RPRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check LFLYW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while SBFMW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas SBFMW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, RPRX is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SBFMW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, OREX has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas OREX's P/E ratio is -0.14. In terms of profitability, RPRX's ROE is +0.12%, compared to OREX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check OREX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas IPXL's P/E ratio is -10.11. In terms of profitability, RPRX's ROE is +0.12%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, RPRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check IPXL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas SHPG's P/E ratio is 11.35. In terms of profitability, RPRX's ROE is +0.12%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, RPRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SHPG's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas ESRX's P/E ratio is 10.69. In terms of profitability, RPRX's ROE is +0.12%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, RPRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check ESRX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, POZN has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas POZN's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to POZN's ROE of +0.61%. Regarding short-term risk, RPRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POZN's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 25.7B. In comparison, CPD has a market cap of 0. Regarding current trading prices, RPRX is priced at $57.97 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.04, whereas CPD's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CPD's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CPD's competition here